Abstract
Although generally well tolerated, oral aminobisphosphonates have been associated with sporadic cases of severe esophageal injury attributed to pill contact. A novel protected formulation of oral alendronate uses an inert cylindrical shell to prevent mucosal contact with intact tablets. An active and placebo-controlled endoscopy study was undertaken to assess mucosal injury associated with this protected formulation. Healthy volunteers with normal baseline endoscopy were randomly assigned to receive protected alendronate 70 mg/day, standard alendronate 70 mg/day, or placebo for 14 days. Endoscopy was repeated on days 8 and 15. Of 78 subjects, 30 received protected alendronate, 28 received standard alendronate, and 20 received placebo. Mean gastric injury scores did not differ significantly among treatment groups. However, subjects on standard alendronate were more likely than those on protected alendronate to develop severe gastric injury, defined as Lanza score 3 or 4 (67.9% versus 33.3%, P=.009), and more likely to develop a gastric ulcer (21.4% versus 3.3%, P=.015). No differences in symptoms or adverse events were observed. In conclusion, a novel protected formulation of oral alendronate is less likely than standard alendronate to induce severe mucosal injury to the upper gastrointestinal tract.
Similar content being viewed by others
References
de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016–1021
Marshall JK (2002) The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opin Drug Saf 1:71–78
Marshall JK, Rainsford KD, James C, Hunt RH (2000) A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment Pharmacol Ther 14:1451–1457
Lanza FL, Hunt RH, Thomson ABR, Provenza JM, Blank MA (2000) Endoscopic comparison of esophageal and gastric effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119:631–638
Thomson AB, Marshall JK, Hunt RH, Provenza JM, Lanza FL, Royer MG, Li Z, Blank MA (2002) 14-day endoscopy study comparing risedronate and alendronate in post-menopausal women stratified by Helicobacter pylori status. J Rheumatol 29:1965–1974
Lanza FL, Panagides J, Salom IL (1986) Etodolac compared with aspirin: an endoscopic study of the gastrointestinal tracts of normal volunteers. J Rheumatol 13:299–303
Lanza FL, Rack MF, Li Z, Krajewski SA, Blank MA (2000) Placebo-controlled randomized evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy post-menopausal women. Aliment Pharmacol Ther 14:1663–1670
Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, Mitchell B, Beveridge BR, Laurence BH, Gibson GG, Grant AK, Shearman DJ, Whitehead R, Buckle PJ (1988) Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903–912.
Famularo G, De Simone C (2001) Fatal esophageal perforation with alendronate. Am J Gastroenterol 96:3212–3213
Acknowledgments
Sponsored by TEVA Pharmaceutical Industries LTD.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marshall, J.K., Thabane, M. & James, C. Randomized Active and Placebo-Controlled Endoscopy Study of a Novel Protected Formulation of Oral Alendronate. Dig Dis Sci 51, 864–868 (2006). https://doi.org/10.1007/s10620-006-9094-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-9094-4